AI & Diagnostics Software in Massachusetts

FIGUR8, Inc. develops FDA-registered musculoskeletal (MSK) assessment technology that replaces subjective measurement tools with objective, lab-grade biomechanics data. The company's flagship platform, the bioMotion Assessment Platform (bMAP), combines on-body wearable sensors with cloud-based analytics to provide precise movement analysis and functional capacity assessments. FIGUR8 serves physical therapists, orthopedic surgeons, chiropractors, occupational health clinics, workers' compensation payers, and sports medicine practitioners. The platform captures over one million data points during dynamic functional movement testing, offering quantitative metrics for injury assessment, recovery monitoring, and return-to-work determination. Use cases include workers' compensation claim management, surgical candidacy evaluation, post-injury rehabilitation tracking, and athletic performance assessment. FIGUR8 is particularly positioned for workers' compensation and occupational health markets, where objective MSK data reduces claim duration and improves outcomes. The company emphasizes clinical training and provider enablement through didactic courses and onsite support. Regulatory status includes FDA registration; the site references compliance with clinical standards and the APTA Digital Transparency Pledge. The technology addresses a significant clinical gap by providing consistent, repeatable objective metrics superior to manual muscle testing and traditional subjective clinical assessments.

Foundation Medicine is a precision oncology diagnostics company specializing in comprehensive genomic profiling (CGP) and companion diagnostic testing for advanced cancer patients. The company develops and commercializes FDA-approved next-generation sequencing (NGS) based in vitro diagnostic tests, including FoundationOne®CDx (tissue-based) and FoundationOne®Liquid CDx (blood-based, circulating cell-free DNA). FoundationOne CDx analyzes 324 genes plus genomic signatures from formalin-fixed, paraffin-embedded (FFPE) tissue samples. FoundationOne Liquid CDx analyzes 324 genes using plasma specimens, reporting short variants in 311 genes, rearrangements in 8 genes, and copy number alterations in 3 genes. Foundation Medicine also offers FoundationOne Heme testing and IHC (immunohistochemistry) services. The company serves three core markets: healthcare providers and oncologists seeking biomarker-driven treatment selection; biopharmaceutical and research partners requiring companion diagnostic development, clinical trial support, and regulatory expertise across the drug development lifecycle; and patients seeking personalized cancer treatment guidance. Foundation Medicine operates a global laboratory with comprehensive EMR integration capabilities and provides decision support services and educational resources to clinicians. The company has delivered over 1.5 million genomic profiling reports and holds more than 50% of all approved US companion diagnostic indications for NGS testing. Services span discovery and translational research, clinical development and CDx strategy, and access and commercialization support. The company is FDA-regulated and maintains rigorous quality standards for molecular diagnostics.

XRHealth is a digital health company specializing in AI-powered extended reality (XR) therapeutic solutions for clinical and home-based care. The company develops virtual reality and immersive software platforms that deliver evidence-based treatment for pain management, cognitive behavioral therapy, physical rehabilitation, occupational therapy, and mental health interventions. XRHealth's flagship product, the XRHealth VR CBT Device, is Medicare-covered as durable medical equipment (DME) under HCPCS Code E1905. The company also offers the XR CareCart, a plug-and-play VR rehabilitation station for deployment in clinics, hospitals, and community settings. XRHealth 2.0 is described as a unified XR therapeutic ecosystem integrating AI-driven personalization, dynamic avatars, and clinical support tools. The platform supports conditions including anxiety, ADHD, autism spectrum disorder, Parkinson's disease, stroke rehabilitation, cancer-related symptoms, and burn wound management. XRHealth holds FDA registration for its medical devices and has secured patents for XR-based impulsivity measurement systems. The company operates through multiple acquisition-driven product lines (acquired Innerworld, RealizedCare, NeuroReality/Koji's Quest, and merged with Amelia Virtual Care) and positions itself as a B2B provider serving healthcare organizations, clinicians, therapists, and patients. Services include clinical delivery, treatment planning, and clinician AI assistant functionality.

Enlight Medical Technologies is a global medical technology company headquartered in Boston, Massachusetts, with research and development centers and manufacturing facilities in Boston, San Francisco, Shanghai, Beijing, and Shenzhen. The company specializes in interventional medical devices for structural heart disease, vascular intervention, and neuromodulation products. The company's core therapeutic areas include: (1) valve intervention—addressing mitral regurgitation and other valvular pathologies through catheterization-based approaches; (2) aortic and peripheral intervention—treating aortic dissection and peripheral vascular disease; (3) neuromodulation—using electrode stimulation for Parkinson's disease, epilepsy, chronic pain, and urinary incontinence; and (4) brain-computer interface (BCI) technology for neurological applications and functional enhancement. The company also develops life science and diagnostic platforms, including proteomic analysis tools aligned with the Human Protein Atlas initiative. Enlight Medical maintains GMP-certified manufacturing facilities and operates across both passive and active device platforms with AI imaging capabilities. The company holds multiple medical device licenses in China and has multiple advanced clinical-stage or submitted products. Research and development teams have 15+ years of medical device engineering and production management experience. The company was founded in Boston and has expanded significantly in China, serving structural heart disease and neuromodulation markets. As of 2023, a spinoff entity (Yinghe Brain Science) completed a Series A funding round focused on next-generation neuromodulation and BCI technology development.

HAI Laboratories, Inc. is an ISO 13485-certified U.S. manufacturer of ophthalmic diagnostic equipment and imaging systems headquartered in Lexington, MA since 1996. The company specializes in clinical, eye bank, and laboratory specular microscopes—the only American manufacturer of these instruments in operation today. HAI produces digital video slit lamps with advanced 3CCD technology for anterior segment imaging, high-resolution endothelial imaging systems for corneal analysis, and custom-configured specular microscopy platforms. The company also develops proprietary image processing and analysis software systems for ophthalmic applications. In addition to diagnostic equipment, HAI manufactures precision ophthalmic microsurgical instruments and motorized microscope stands. Known for user-driven product development and modular system design, HAI offers factory-direct pricing, equipment rentals, professional installation, on-site training, and validation services to eye banks, hospitals, universities, and private clinics worldwide.

Boston Micro Fabrication (BMF) is a precision micro-manufacturing company specializing in ultra-high-resolution 3D printing using Projection Micro Stereolithography (PµSL) technology. The company manufactures micro-precision parts with resolutions down to 2µm and tolerances of ±10µm (±0.025mm) for medical devices, microfluidics, electronics, optical systems, and aerospace applications. BMF's core product line includes the microArch series of 3D printing platforms (microArch S150, S240, S350, P150), which deliver industrial-grade micro-precision manufacturing capabilities in compact, desktop-scale systems. The company produces custom micro-components including endoscope shells, microfluidic chips with integrated channels as small as 400µm, electronic connectors with features down to 140µm, and chip array sockets with micro-holes at 50µm spacing. BMF recently launched BMF Clear, an optically transparent photopolymer resin with >90% light transmittance for applications requiring optical transparency at micron scales. The company serves contract manufacturing and R&D environments across medical device, electronics, microfluidics, and precision engineering sectors. Customer base includes major OEMs and contract manufacturers such as TE Connectivity, Ambu, Pristine Surgical, and research institutions. BMF enables rapid prototyping and low-volume production with 1–2 day turnaround versus traditional micro-injection molding (1–2 months), eliminating expensive tooling costs while maintaining dimensional accuracy comparable to molded components. Manufacturing capabilities span open material ecosystem support and custom benchmark part development. Regulatory and quality credentials not explicitly stated on homepage; medical device focus suggests ISO 13485 and 510(k) compliance typical for the sector.

Vistapath Biosystems is a software-focused medical technology company headquartered in Cambridge, MA. The company develops Sentinel, an end-to-end digital grossing platform designed to modernize pathology laboratory workflows. Sentinel automates and optimizes critical lab processes including tissue specimen grossing, enhancing quality, efficiency, and consistency across commercial laboratories, hospital pathology labs, contract research organizations (CROs), and life sciences companies. The platform leverages artificial intelligence to streamline intraoperative and routine pathology operations. Vistapath collaborates with established diagnostic and pathology partners (PathAI, Gestalt Diagnostics, PathGroup, Freedom Pathology Laboratories) to validate and deploy the Sentinel platform across clinical and research settings. The company targets mid- to large-scale pathology operations seeking digitization and workflow automation. Management includes CEO Tim Spong and VP Sales & Marketing J. Fernando Corredor, who brings over 20 years of medical device industry experience including work with acquired companies (Medtronic, Integra LifeSciences, Samsung) in imaging and AI-driven diagnostics. While regulatory certifications are not explicitly mentioned in available materials, the company's clinical deployment trajectory and partnership with established pathology networks indicate compliance with relevant healthcare software standards.

Luminopia Inc. is an FDA-cleared digital therapeutics company specializing in VR-based treatment for pediatric amblyopia (lazy eye) in children aged 4–12. The company delivers its prescription-only Luminopia software through commercially available VR headsets, enabling patients to receive binocular vision therapy while watching curated TV content instead of traditional patching. The treatment regimen requires one hour daily, six days weekly, with clinical trials demonstrating significant vision improvement within 4–12 weeks. Luminopia is prescribed by ophthalmologists, optometrists, and orthoptists; the company handles fulfillment, patient support, and compliance monitoring. Designed for at-home use alongside corrective lenses, Luminopia achieved 94% parental preference over conventional patching and demonstrated 85% median treatment completion rates, addressing the long-standing compliance challenges in amblyopia management.

Epicore Biosystems is a digital health and biomedical wearables company specializing in sweat-sensing microfluidic technology. The company develops non-invasive biowearable devices that analyze sweat biomarkers—including electrolytes, metabolites, nutrients, and stress markers—to provide real-time physiological insights. Epicore's proprietary sweat microfluidic sensing platform integrates cloud analytics for personalized health monitoring and decision support. The company's primary solutions target three market segments: industrial safety (workplace hydration and heat stress monitoring), sports and fitness (performance optimization and recovery tracking), and clinical research (biomarker discovery and FDA-registered data collection systems). Epicore's Connected Hydration platform delivers continuous monitoring with real-time alerts, and its Discovery Patch provides laboratory-grade sweat analysis for research applications. The company has established partnerships with major enterprises including Chevron, PepsiCo, Gatorade, and the U.S. Air Force Research Laboratory, deploying solutions across energy, construction, and professional sports sectors.

CaviSense is a dental diagnostics platform that detects early-stage cavities in real time using patented pH-sensing technology developed in collaboration with Harvard and Tufts University. The at-home detection and monitoring device identifies cavities while still reversible—before traditional diagnostics catch them—enabling early intervention and preventive care. CaviSense serves both dental practices seeking efficient patient monitoring and individual consumers seeking proactive oral health management. The device delivers results in approximately 10 seconds and supports remineralization monitoring and biofilm pH analysis to guide clinical decision-making and patient behavior change.